Krystal Biotech (NASDAQ:KRYS - Get Free Report) had its price target lifted by stock analysts at Citigroup from $204.00 to $206.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has a "neutral" rating on the stock. Citigroup's target price would indicate a potential upside of 18.21% from the stock's previous close.
KRYS has been the subject of several other research reports. Evercore ISI boosted their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an "outperform" rating in a research note on Monday, August 12th. Stifel Nicolaus upped their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a "buy" rating in a research report on Wednesday, September 11th. William Blair upgraded Krystal Biotech to a "strong-buy" rating in a research report on Friday, August 30th. Cantor Fitzgerald restated an "overweight" rating on shares of Krystal Biotech in a report on Thursday, August 29th. Finally, Chardan Capital increased their target price on Krystal Biotech from $153.00 to $208.00 and gave the company a "buy" rating in a research note on Monday, August 5th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Krystal Biotech presently has a consensus rating of "Buy" and a consensus price target of $197.00.
Get Our Latest Analysis on KRYS
Krystal Biotech Trading Up 2.0 %
Shares of KRYS traded up $3.42 during midday trading on Tuesday, hitting $174.27. 160,706 shares of the company's stock traded hands, compared to its average volume of 328,839. Krystal Biotech has a 1 year low of $93.95 and a 1 year high of $219.34. The firm's fifty day moving average is $182.28 and its 200-day moving average is $180.12. The stock has a market capitalization of $5.01 billion, a price-to-earnings ratio of 97.94 and a beta of 0.82.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million for the quarter, compared to analysts' expectations of $82.94 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The company's quarterly revenue was up 879.9% on a year-over-year basis. During the same period last year, the firm earned ($0.67) EPS. On average, equities research analysts anticipate that Krystal Biotech will post 2.88 EPS for the current year.
Insider Activity
In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the transaction, the insider now directly owns 1,500,882 shares of the company's stock, valued at $296,814,424.32. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 14.10% of the company's stock.
Institutional Investors Weigh In On Krystal Biotech
A number of institutional investors have recently bought and sold shares of KRYS. EFG Asset Management North America Corp. lifted its holdings in shares of Krystal Biotech by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company's stock valued at $2,308,000 after buying an additional 60 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company's stock valued at $28,000 after buying an additional 93 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Krystal Biotech by 11.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company's stock valued at $173,000 after acquiring an additional 94 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Krystal Biotech by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 5,147 shares of the company's stock valued at $945,000 after acquiring an additional 108 shares in the last quarter. Finally, Fiera Capital Corp raised its stake in shares of Krystal Biotech by 0.8% in the 2nd quarter. Fiera Capital Corp now owns 16,208 shares of the company's stock valued at $2,976,000 after acquiring an additional 130 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.
About Krystal Biotech
(
Get Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Read More
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
